IL2 and acute coronary syndrome: IL-2 efficacy is being further investigated in the context of ACS by the IVORY (Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes) trial (NCT04241601), with index vessel inflammatory parameters as assessed by PET-CT scan as the primary endpoint [55].